NCT07128212 - Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1 | Biotech Hunter

Enrollment

401

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Ischemic White Matter Lesions (WMIL)Cerebral Small Vessel DiseaseVascular Cell Adhesion Molecule-1VCAM-1

Interventions

DRUG

Atorvastatin 10 mg daily

Oral atorvastatin 10 mg administered once daily at 18:00 (6 p.m.) for 24 months. Dose form: tablet. Route: oral. Indicated for participants with WMH. Adherence monitored by pill count and diary. No dose titration planned.

DRUG

Placebo matching atorvastatin

Placebo tablet matching atorvastatin in appearance and packaging, containing inactive excipients only; taken orally once daily at 18:00 for 24 months.

Trial Locations (1)

234000

Suzhou Hospital of Anhui Medical University, Suzhou

All Listed Sponsors

lead

Suzhou Municipal Hospital of Anhui Province

OTHER